Generated by AI
Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry. The company uses automation, artificial intelligence, machine learning, and engineering to map biological systems and identify novel therapeutic candidates. Its work centers on building a technology-enabled platform for discovering and advancing medicines across areas such as oncology, rare disease, and other complex conditions. Recursion also operates in a research and development environment that combines wet-lab biology with computational tools to improve the efficiency of early-stage drug discovery. Headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals plays a specialized role in the biotechnology market as a developer of platform-based drug discovery capabilities and clinical-stage therapeutic programs.
Website41 South Rio Grande Street
Salt Lake City, UT, 84101
United States
The latest articles about RXRX.
Recursion Pharmaceuticals is maintained at a "Hold" rating. Read the latest analysis here on RXRX stock.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about RXRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.